Drug News

Lorazepam is associated with worse progression-free survival. A co-treatment approach improves efficacy. The FDA's approval process for certain drugs is questionable. Updates to toxicity diagnosis and management are provided. A method to identify children with acute sinusitis who are likely to benefit from antibiotics is described. Psilocybin is presented as a novel intervention for depression.

Study at a glance

Abstract

In Brief Lorazepam associated with worse progression-free survival... Examining long-term medication effects... The co-treatment approach improves efficacy... Article details FDA's questionable approval... Updates to toxicity diagnosis and management... Identifying children with acute sinusitis who are likely to benefit from antibiotics... Psilocybin as a novel Intervention for depression